Abstract
Soft tissue sarcomas (STS) is a set of rare malignant tumor originated from mesoderm. For the prognosis of sarcoma, early diagnosis is important, however, currently no mature and non-invasive method for diagnosis exists. MicroRNAs (miRNAs) are a class of noncoding RNAs and their expression varies greatly, especially during tumor activity. The purpose of this study was to construct a predictive model for the diagnosis of sarcomas based on the relative expression level of miRNA in serum. miRNA array expression data of 677 samples including 402 malignant sarcoma samples and 275 healthy samples was used to construct the prediction model. Based on 6 gene pairs, random generalized linear model (RGLM) was constructed, with an accuracy of 100% in the internal test dataset and of 74.3% in the merged external dataset in prediction whether a serum sample was obtained from a sarcoma patient, with a specificity of 100% in the internal test dataset and 90.5% in the external dataset. In conclusion, our serum miRNA-pair classifier has the potential to be used for the screening of sarcoma with high accuracy and specificity.
Highlights
Sarcomas are divided into bone and soft tissue sarcomas, both of which have many subtypes [1]
Based on 6 gene pairs, random generalized linear model (RGLM) was constructed, with an accuracy of 100% in the internal test dataset and of 74.3% in the merged external dataset in prediction whether a serum sample was obtained from a sarcoma patient, with a specificity of 100% in the internal test dataset and 90.5% in the external dataset
A total of 677 serum samples, including 402 malignant sarcoma samples and 275 healthy controls and associated basic clinical information was downloaded from Gene Expression Omnibus (GEO), serial number GSE124158 [8]
Summary
Sarcomas are divided into bone and soft tissue sarcomas, both of which have many subtypes [1]. Advances in adjuvant chemotherapy and surgical techniques have provided additional options for the treatment of sarcomas. High-grade sarcomas are prone to recurrence and metastasis and once metastasized, the death rate can increase to 50% [2]. CT and MRI imaging and biopsy are routine diagnostic methods for sarcomas, but the high costs and invasive nature of the approach are not conducive to the screening of sarcomas. Development of simple and convenient screening method is of critical importance for the treatment and prognosis of sarcomas. MicroRNAs (miRNA) are short (*22 nucleotides) non-coding RNA molecules that regulate gene expression at the post-transcriptional level, and have critical functions across various biological processes [3]. MiRNAs showed higher accuracy than messenger RNA in classifying poorly differentiated tumors in a study of 334 samples [4].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
